Literature DB >> 1774568

Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty.

J P Bailey1, M P Kruger, F X Solano, A B Zajko, H E Rubash.   

Abstract

A prospective randomized trial compared the effectiveness of low-dose warfarin (LDW) to sequential compression devices (SCD) for deep venous thrombosis (DVT) prophylaxis in 95 patients after total hip arthroplasty (THA). Patients were 39 years of age or older, with no history of previous venous disease. Bilateral lower-extremity venography was used for thrombi detection. Venous thrombi occurred in 12 patients (all calf) on LDW (26.6%) and 3 patients with SCDs (one calf, two thigh) (6.0%). The incidence of DVT was significantly higher in the LDW group (P less than .006). In this study of average-risk patients, the use of SCDs significantly outperformed LDW as a prophylactic agent. However, the thrombi that did occur with SCDs were more critical.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774568     DOI: 10.1016/s0883-5403(08)80053-8

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Foot pump prophylaxis for deep venous thrombosis-rate of effective usage following knee and hip arthroplasty.

Authors:  C Charalambous; S Cleanthous; M Tryfonidis; A Goel; R Swindell; D Ellis
Journal:  Int Orthop       Date:  2003-04-25       Impact factor: 3.075

2.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.

Authors:  A Planes; N Vochelle; J Y Darmon; M Fagola; M Bellaud; D Compan; E Saliba; N Weisslinger; Y Huet
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Evidence-based compression: prevention of stasis and deep vein thrombosis.

Authors:  Rhys J Morris; John P Woodcock
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

6.  Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.

Authors:  B J O'Brien; D R Anderson; R Goeree
Journal:  CMAJ       Date:  1994-04-01       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.